Keros Therapeutics's total assets for Q3 2024 were $579.27M, an increase of 27.31% from the previous quarter. KROS total liabilities were $46.44M for the fiscal quarter, a 36.15% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.